Arthneeti

Aarti Drugs Q1 FY27 Share Price & Earnings Call Analysis

₹449.00+0.25% today
Market cap
₹4,102 Cr
P/E
21.28
ROE
13.36%
PEG
3.93
Price to sales
1.53
Debt to equity
0.37
52W high / low
₹520 / ₹320
Sales growth (5Y)
3.55%
EBITDA margin
12.45%
Net profit margin
7.60%
Promoter holding
54.07%
Sales (last year)
₹2,678 Cr

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

Guidance scorecard · Q1 FY27 call

What Aarti Drugs Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#50of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsUp 0–2%CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • Aarti Drugs targets 10%-15% volume growth over the next two years, driven by existing product capacity and new expansions.
  • Volume growth is expected even if the salicylic acid derivatives segment does not pick up immediately.
  • The Sayakha facility ramp-up will significantly increase captive consumption, supporting volume and margin growth.
  • Pricing pressures are expected to ease, potentially boosting demand and volume growth in upcoming quarters.
  • Focus on increasing sales in regulated markets (US, Europe) with new USFDA and CEP approvals is expected to expand higher-margin revenues.
  • Specialty chemical segment saw 149% growth and is expected to sustain or improve performance going forward.

2 more points from Aarti Drugs Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Up 0–2%

See what Aarti Drugs Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • The company recently completed a capital expenditure of INR 600 crores focused on Phase 1 greenfield facilities, achieving an asset turnover of around 1.5x.
  • Phase 2 brownfield capex is planned for Sayakha and G61 Tarapur sites, expected to deliver higher asset turnover of 3x to 4x due to existing infrastructure.
  • Expansion underway at Baddi facility to nearly double oral solid dosage manufacturing capacity.
  • Construction of additional USFDA-approved Metformin capacity (500+ tons/month) at Sarigam, expected to take 10-12 months to complete.
  • Plans for a quasi greenfield USFDA plant adjacent to the current USFDA facility to more than double production capacity with 3 new multipurpose lines are underway.

2 more points from Aarti Drugs Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Aarti Drugs Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Strong and steady demand across API and Specialty Chemicals portfolio.
  • Healthy consumption across key therapeutic categories in both domestic and international markets.
  • Positive traction in exports with customers seeking reliable and compliant suppliers.
  • Business development underway for US markets in formulations and APIs, indicating potential order growth.

2 more points from Aarti Drugs Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Aarti Drugs Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Aarti Drugs Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Aarti Drugs Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Aarti Drugs Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +742661642606620555598557677591653602720
Expenses +649577565536534490531495583516569547624
Operating Profit94847670866567629374845596
OPM %13%13%12%12%14%12%11%11%14%13%13%9%13%
Other Income +11121111220011
Interest9988999999898
Depreciation12131313141314141515161818
Profit before tax73645652644446517151602970
Tax %23%24%30%29%26%24%24%27%12%-6%25%-40%21%
Net Profit +56484037473335376354454155
EPS in Rs6.065.174.313.995.153.623.844.066.895.914.964.446.05

Financials of Aarti Drugs Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +1,0971,1401,1951,2441,5611,8062,1552,4892,7162,5292,3872,565
Expenses +9259601,0051,0421,3501,5411,7142,1562,4072,2082,0972,256
Operating Profit172180190202211266440333309321290309
OPM %16%16%16%16%14%15%20%13%11%13%12%12%
Other Income +10416651124162
Interest424840384437262437383934
Depreciation313738404349505050515667
Profit before tax10095116125131185369270224236212211
Tax %23%28%29%34%32%24%24%24%26%27%21%8%
Net Profit +7769828290141280205166172168195
EPS in Rs7.977.098.578.739.5215.1730.0922.1417.9618.6518.4221.36
Dividend Payout %41%24%3%3%3%3%8%5%6%5%5%0%

Financials of Aarti Drugs Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital242424242423939393929191
Reserves2843333764325206298209441,1001,1901,2781,458
Borrowings +448483480546507389351543609564615577
Other Liabilities +248261311388405535502629620587591690
Total Liabilities1,0041,1021,1911,3891,4551,5761,7662,2082,4212,4322,5752,815
Fixed Assets +4484935816026256446656906768118661,086
CWIP1634142833121977210261330214
Investments5512111213171919202227
Other Assets +5345705847487859071,0641,4221,5161,3401,3561,488
Total Assets1,0041,1021,1911,3891,4551,5761,7662,2082,4212,4322,5752,815

Financials of Aarti Drugs Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1051331757014325115570133359245254
Cash from Investing Activity +-107-99-107-74-62-33-72-150-164-224-165-173
Cash from Financing Activity +1-33-684-80-215-819217-136-82-77
Net Cash Flow-11-0012213-14-1-23
Free Cash Flow-23468-58021478-82-311336780
CFO/OP69%85%103%47%82%110%57%46%62%131%103%81%

Financials of Aarti Drugs Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days105106911101079994110116102115118
Inventory Days828610013286102117115101107114111
Days Payable83909412385104931039494100108
Cash Conversion Cycle1041039711910997118123123115129121
Working Capital Days141922334454776372747676
ROCE %18%18%17%17%21%34%21%15%15%13%12%

Guidance history

How Aarti Drugs Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%Up 0–2%Planned——
Q4 FY26 call →10–20%Up 0–2%PlannedPlanned—
Q3 FY26 call →10–20%Up 2%+PlannedPlanned—
Q2 FY26 call →10–20%Up 2%+Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

34out of 100

Momentum score · price trend

34 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−6.9%53%
Last 6 months+20.0%75%
Last 3 months+8.9%79%

The price is 54.5% below its all-time high of ₹984.2 (9 Oct 2020). Stocks more than 20% below their peak have their score halved, so 67 became 34.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Aarti Drugs Ltd: 0.4 × 53 + 0.4 × 75 + 0.2 × 79 = 67, halved to 34 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 28 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Aarti Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd